O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial

Abstract

This randomized double-blind, placebo-controlled clinical trial evaluated the anti-depressant efficacy and safety of SAGE-217, a positive allosteric modulator of GABAA receptors, in subjects with moderate-to-severe Major Depressive Disorder (MDD).